Tackling therapeutic inertia to boost patient outcomes - exclusive whitepaper
The impacts of therapeutic inertia - a delay or failure to implement or modify treatment regimens where needed - are profound across a range of disease areas: suboptimal patient outcomes, faster disease progression, increased healthcare costs, and even preventable deaths.
Yet pharma is perfectly placed to tackle inertia, and in addressing its negative outcomes, can gather vital data that helps inform activity pre-, during and post-launch.
That’s why pharma and patient experts from organizations including Bayer, Ipsen, Novartis and WeFight have created an exclusive whitepaper outlining the causes of therapeutic inertia, as well as key solutions such as new technological tools and healthcare provider (HCP)-pharma partnerships.
Please subscribe to view the analysis report